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Graphical Abstract: The existing linkage between oxidative stress and the hallmarks of AD represents a challenge in 
developing multitarget drugs by addressing simultaneously ROS production, metal accumulation and protein 
deposition. 
 
Abstract: Alzheimer diseases (AD) is a multifactorial pathology characterized by a complex etiology. The hallmarks of 
AD, such as Aβ deposits in senile plaque and neurofibrillary tangles (NFT), are strongly intertwined with reactive 
oxygen species (ROS) production and oxidative stress (OS), which are considered the common effectors of the cascade 
of degenerative events. An increasing body of evidence reveals that both mitochondrial abnormalities and metal 
accumulations synergistically act as major producers of ROS, thus contributing to neuronal toxicity. Consequently, the 
detrimental role of ROS production together with the neurodegenerative events involved in AD has been widely 
investigated as new potential therapeutic strategies. This review will concisely summarize the link between OS and the 
hallmarks of AD, emphasizing on their strong correlation with neurodegenerative events and elucidating the pivotal role 
of ROS in AD pathology. Furthermore, through this review, we will provide a short account of some of the efforts, 
challenges and opportunities in developing multitarget drugs by addressing ROS production, metal accumulation and 
protein depositions.  
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1.Introduction 
Oxidative stress (OS) was redefined by Sies and Jones as “the result of a mismatch between the excessive formation of 
reactive oxygen or nitrogen species (ROS, RNS) and limited antioxidant defenses that occurs constantly in every cell 
during the biochemical changes implicated in the metabolism”[1]. The human brain is one of the most metabolically 
active organs in the body, utilizing about 20% of the body’s total basal oxygen and subsequently generating relatively 
high level of ROS [2]. Under physiological conditions, mitochondria produce ROS such as superoxide anion (O2
−
·), 
hydroxyl radical (OH·) and hydrogen peroxide (H2O2), as well as RNS, such as nitric oxide (NO·) and peroxynitrite 
(ONOO
−
). Consistently, superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase (CAT) and other proteins 
with chelating properties and constituting the antioxidant system, minimize the harmful effects of these reactive species 
inactivating free radicals.  
Recent findings recognized that the deregulation of the redox-state actively participates to the Alzheimer’s disease (AD) 
and triggers several cellular pathways which contribute to both the onset and the progression of this neurodegenerative 
disease. Therefore, nowadays, the OS should be considered a key player in AD as well as in many other forms of 
dementia[3]. 
Currently, many experimental evidences highlight an intimate linkage between OS and cellular events that contribute to 
neuronal damage such as -amyloid generation, neurofibrillary tangles (NFTs) formation, neuroinflammation and 
aberrant mitochondrial activity. All these components represent the “constituent elements” of a vicious cycle of events, 
in which OS plays a fundamental role (Fig. 1). Consequently, the simultaneous regulation of OS, together with the 
inhibition of other AD hallmarks, could lead to the development of more than one compelling therapy than the already 
existing ones.  
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Figure1.Schematic representation of the AD targets associated withOS. 
 
 
This review focuses on the recent advances in the search for innovative anti-AD therapeutic strategies designed taking 
into account the existing interactions between the “vicious cycle components” and OS. Moreover, medicinal chemistry 
approaches targeting these interactions will be deeply discussed as examples of possible innovative therapeutic 
strategies to treat AD. 
 
2. Amyloid β-peptide and OS 
As it has already been mentioned, AD has a complex, multifactorial etiology but until now, the putative mechanisms 
involved in the pathology are not completely clarified. Among the different postulated “hypotheses”, the amyloid 
one assumes that extracellular amyloid beta (Aβ) deposits are the fundamental causes of the disease[4]. 
Amyloid β-peptide (Aβ) is constituted by a 40–42 amino acids[5, 6] and it is considered as the major component of 
senile plaques, occurring in AD.  Aβ is generated from amyloid precursor protein (APP), a type I transmembrane 
protein which was found in several tissues. APP seems to be involved in cell growth, neurite outgrowth, cell adhesion, 
cell signaling and cell survival[7]. It undergoes a proteolytic cleavage through two different ways: the non-
amyloidogenic and the amyloidogenic pathways. 
The amyloidogenic pathway is responsible for the formation of neurotoxic Aβ fragment, the major hallmark of AD. In 
this pathway APP is cleaved by -secretase 1 (BACE1), a type I transmembrane aspartyl protease which has been found 
in elevated amount in AD, as two products: a soluble residue APPsβ (β-secretase-cleaved soluble APP) and C terminal 
fragment (CTFβ). In turn, the CTFβ is cleaved by γ-secretase thus releasing Aβ fragment. The action of γ-secretase 
occurs at multiple sites of Aβ (from ζ to γ), and leads to the formation of Aβ fragments ranging from 37 to 46 amino 
acids in length. Among them, the neurotoxic Aβ(1-42) tends to form oligomers and aggregates. During the progression 
of AD, the level of Aβ(1-40) seems to be constant in cerebrospinal fluid (CSF), on the contrary, the Aβ(1-42) level 
decreases in CSF but increases in senile plaques[8]. This effect is probably due to a deficient efflux of Aβ(1-42). Recent 
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evidence revealed that the higher damage in CNS is principally due to the aggregation of Aβ(1-42) in oligomers rather 
than plaques formation[9]. 
Although A accumulation is considered a hallmark of AD, it is still unclear if the OS is the trigger or the consequence 
of A deposition in brain. 
Therefore, evidence of both the Aβ-induced OS hypothesis and OS-induced Aβ accumulation have been proposed. 
Implications of metionine-35 (Met-35) residue of Aβ(1-42) in the ROS generation have been largely studied. It seems 
that Aβ(1-42) oligomers are able to insert themselves into the lipid bilayer forming the alpha-helices. During this 
process Met-35 is easily oxidized thus obtaining the Met sulfuranyl free radical (MetS
+
) which is, in turn, stabilized by 
the hydrophobic environment of the lipid bilayer[10]. MetS
+
 starts a series of free radical chain reactions, generating 
lipid peroxidation products and oxidative modified membrane proteins[11]. This hypothesis has been confirmed by 
different in invitro studies: for instance, the replacement of the critical aminoacids needed for a correct spatial 
displacement of Aβ(1-42) nullifies the toxic effect of Aβ(1-42)[12, 13], thus showing the detrimental role of Met-35 in 
the A-induced neurotoxicity. Also in in vivo studies performed in AD mice have shown that the mutation of the Met-
35 residue to Leu produced the loss of OS in brain[14]. These studies seem to confirm the hypothesis that Met-35 of 
Aβ(1-42) plays an important role in OS. 
However, there are alternative hypotheses that explain the relationship between Aβ(1-42) and OS in which the possible 
role of OS is highlighted as a causal factor and not as an effect induced by the Aβ-production. Indeed, post-mortem 
studies showed that OS appears in the early phase of AD, and it declines when beta amyloid begins to accumulate in the 
CNS, whereas, in transgenic AD models, the oxidation of proteins and lipids seems to anticipate the deposition of Aβ(1-
42)[15]. Further cell based studies indicated that the OS provokes an overexpression of APP and an increase of BACE 
activity, thus improving the production of Aβ(1-42)[16]. In opposition with the hypothesis discussed above, Sinha et al. 
have recently proposed that Aβ(1-42) could have an antioxidant action, principally linked to its metal-chelating 
property[17]. According to this study, it has been suggested that the accumulation of Aβ(1-42) could represent a cellular 
defense against the OS and metal dyshomeostasis, even if all of their toxic properties are still maintained. 
Although the exact mechanism linking A(1-42) to OS is not clear yet, their important role in both the onset and 
evolution of AD has urged several medicinal chemists to design new multifunctional compounds that target 
simultaneously Aβ(1-42) and OS. Unfortunately, none of them has been approved by FDA [18, 19], further prompting 
the research toward the development of multi-target entities as an effective strategy for the treatment of complex and 
multifactorial pathologies such as AD. 
One of the initial attempts in designing AD multitarget directed ligand (MTDL) was carried out by Lenhart et al., that 
designed bivalent multifunctional Aβ oligomerization inhibitors (BMAOIs) targeting the small Aβ oligomers (AβOs), 
OS and the membrane microdomains of neuronal cells, namely cell membrane/lipid rafts (CM/LR), which are rich in 
cholesterol and sphingolipids. CM/LR were found efficient in accelerating the bind of Aβ with the cell membrane thus 
promoting the AβOs formation[20-22]. BMAOIs were obtained by the combination of curcumin, one of the most 
renowned phytochemical that owns well-known antioxidant, anti-inflammatory and anti-Aβ properties[23], with 
cholesterol, which exerts the function to anchor CM/LR in mammalian cells. A series of BMAOIs with different spacers 
were synthetized; in particular, compound 1 which possesses a 21-atom-spacer in C-4 position of curcumin, showed to 
potently reduce the intracellular level of AβOs in both MC65 (a human neuroblastoma cell line) and ML60 (a line of 
Chinese hamster ovary that specifically produce high levels of extracellular AβOs cell lines). Moreover, compound 1 
displayed antioxidant properties comparable to curcumin and showed to cross the blood brain barrier (BBB) in Caco-2 
cell line.(Fig. 2) 
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Figure2.Design strategy of compound 1 
Another class of MTDL was synthesized starting from the styrylbenzene scaffold. The new compounds interacted with 
Aβ thus reducing its aggregation and, in the meantime, acted as free radical scavengers[24]. The most interesting 
compounds were obtained by the combination of bis-styrylbenzene scaffold of DF-9, previously synthetized from the 
same group[25], and resveratrol. Resveratrol (trans-3,4′,5-trihydroxystilbene) is a natural polyphenolic compound 
highly concentrated in grape skin and red wine; this phytochemical is known to possess a strong antioxidant behaviour 
due to the presence of phenolic units [26, 27], but it is also able to inhibit Aβ aggregation in in vitro models [28] thanks 
to its diaryl conjugated structure. Among the hybrids designed with this strategy, compound 2 (Fig. 3) displayed a good 
Aβ binding affinity (Kd = 5.3±0.3 nM), a good capability to cross the BBB and also the ability to bind with Aβ plaques 
in in vivo assays. On the whole, this compound could be considered as a lead molecule for the early Aβ detection. 
However, because of the limited free radical scavenging properties, a medicinal chemistry optimization is needed for 
future possible applications in AD therapy. 
 
 
 
 
Figure 3.Design strategy of compound 2. 
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Recently, a new drug candidate, memoquin (MQ), has been identified as a promising anti-AD drug candidate mainly for 
its exquisite multitarget profile [29]. MQ is a quinone-bearing polyamine compound. It has been rationally designed and 
synthesized by replacing the linear alkyl chain of caproctamine with a radical scavenger function, in a deliberate 
attempt to find an MTDL able to interfere with different key target points of AD neurodegeneration [30](Fig. 4). 
Memoquin has already been shown to decrease plaque number and morphology in in vivo models and displayed a 
significant capability to reduce the Aaggregation in in vitro assay. MQ proved to inhibit, in a concentration-dependent 
manner, BACE1, one of the two enzymes involved in the APP amyloidogenic cleavage (IC50=108 nM). Moreover, in 
SH-SY5Y neuroblastoma cells, MQ reduced AChE-mediated Aβ aggregation [31] and displayed a dose-dependent 
neuroprotective effect against Aβ(1–42) oligomers-induced neurotoxicity[32]. 
As far as the antioxidant properties are concerned, MQ demonstrated to act as a substrate for the NADPH quinine 
oxidoreductase 1 (NQO1) with Kmof 12.7 μM. This enzyme catalizes the reduction of the MQ-quinone moiety into the 
hydroquinone form which is the real antioxidant specie [29]. This mechanism of action has been also confirmed in 
cellular assays performed in SH-SY5Y cell line, where MQ showed to neutralize the formation of free radicals and 
ROS. 
 
 
Figure4.Design strategy of Memoquin. 
In the last decade, it is emerged that the cerebrovascular function plays a detrimental role in AD pathogenesis and, more 
importantly, that cerebral hypoperfusion should represent a primary trigger for neuronal dysfunction that lead to Aβ-
accumulation in brain and to a reduced Aβ clearance[33]. The worsening of the neurovascular dysfunction seems to be 
strongly related to the loss of functionality of specific receptors and/or to the reduction of carrier-mediated transport 
activity across the BBB [33, 34]. Many receptors regulate the transport equilibrium of Aβ across the BBB and among 
these, the receptor for advanced glycation end products (RAGE; also known as AGeR) and the low-density lipoprotein 
receptor-related protein 1 (LRP-1) [35]. Many experimental evidences showed an increased RAGE expression at the 
BBB in models of Alzheimer’s disease [36]. In addition to that, in order to mediate the flux of A across the BBB, 
RAGE promotes synaptic dysfunction as well as neuroinflammation and OS, following the activation of specific 
mediators such as the nuclear transcription factor kB (NF-kB). Consequently, the blockade of Aβ–RAGE signaling in 
AD could represent a promising strategy to control Aβ accumulation and thus Aβ-mediated injuries. Indeed, PF-
04494700 (Azeliragon), a small-molecule inhibitor of the RAGE recently developed by Pfizer, has completed a phase II 
clinical trial aimed at evaluating the efficacy and safety in subjects with mild to moderate Alzheimer's disease 
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(ClinicalTrials.gov Identifier: NCT00566397) [37]. Previously, in vitro studies showed that Azeliragon inhibits amyloid 
plaque formation, reduces the size of pre-existing plaques, and decreases the behavioral effects due to toxicity of A-
deposition [19]. More interestingly, the effects induced by the RAGE inhibitor are the blockade of A-deposition, but 
above all, the reversal of symptoms of amyloidosis [19, 38]. Further studies of Galasko et al. proved that PF-04494700 
(after ten weeks of treatment) is safe and well-tolerated in patients with mild to moderate AD, thus indicating the 
feasibility of a wider long-term clinical trial[39]. 
 
Figure5. Structure of PF-04494700. 
 
3. NFT and OS 
AD is pathologically characterized by the presence of extracellular senile plaques, constituted by a core of Aβ, and 
intracellular neurofibrillary tangles (NFTs). 
NFTs are formed by an aggregation of paired helical filaments (PHF), which are made up of phosphorylate tau protein. 
The physiological function of tau is to maintain the assembly and the stability of microtubules: when tau is 
hyperphosphorylated, a disassembly of microtubules occurs, compromising their correct action and consequently 
causing a decrease of the axonal and dendritic transport. Tau filaments accumulate in dystrophic neuritis as fine 
neuropil threads or as bundles of PHF in neuronal bodies, constituting the NFTs that lead to the formation of 
extracellular tangles. The formation of tangles could be due to release in the brain of antibodies against different 
phosphorylation sites of tau[40]. 
It is still debated whether NFTs play a primary or a peripheral role in AD, however the NFT density seems to be linked, 
at least in part, to the neuronal loss and to the level of dementia. Many studies revealed that neuronal death it is not 
directly induced by NFT formation, but it is mediated by OS, which is closely linked to the NFT formation. Indeed, OS 
activates some kinases such as glycogen synthase kinase-3β (GSK-3β)[41] and mitogen-activated protein kinases 
(MAPKs)[42] that phosphorylate tau protein. Phosphorylated tau undergoes oxidative modification and aggregates into 
fibrils because of a high presence of lysine-serine–proline (KSP) domains[43].  
Recently, the NFT formation has been suggested as a “compensatory response” to OS. Indeed, as observed for Aβ, the 
antioxidant role of NFT could be due to the capability to form complexes with free metals. In particular, iron and 
copper bind to phosphorylated tau protein whereas iron ions tightly interact with NFT [44, 45]. 
In various cell cultures, invertebrate and mammalian models of AD increasing GSK3 activity leads to the 
hyperphosphorylation of tau, increased A generation and deficits in learning and memory accompanied with 
neurodegeneration[46]. There are numerous studies showing that abnormal increases in the level and activity of GSK-
3β induces neuronal cell death, paired with helical filament tau formation and neurite retraction. The strong link 
between NFT and OS prompted researchers to target all these hallmarks of AD simultaneously. 
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Recent years have witnessed the development of an increasing number of novel GSK-3β inhibitors, many of which are 
ATP-competitive. Within this class, SB-415286 , an anilinomaleimide, developed by Glaxo Smith Kline, showed the 
ability to inhibit GSK-3β with an IC50 value in the nanomolar range [47]. The compound acutely reduces cellular GSK-
3 activity as assessed by activation of glycogen synthase. Moreover, SB-415286 shows antioxidant properties, which 
may explain the cytoprotective effect against H2O2 damage [48]. In the light of these findings, the use of dual 
antioxidant GSK-3 inhibitors could be considered one of the most promising approaches for treatment of AD (Fig. 6). 
 
 
 
Figure6.Structure of SB-415286. 
Several studies suggest that over-expressed tau (normal and/or hyperphosphorylated) has also been found to impair 
axonal transport and abnormal distribution of mitochondria in AD neurons[49]. Given that, one of the primary targets of 
pathological forms of tau may be mitochondria. Many proposed therapies target mitochondrial ROS production and 
cellular oxidative stress which result from malfunctioning mitochondria and compromise cell viability. 
One Mitochondria-Targeted Antioxidants (MTAs) termed mitoQ (mitoquinol, or mitoquinone, or a mixture of these 
redox forms) is produced by conjugation of the lipophilic triphenylphosphonium cation (TPP
+
) to coenzyme Q (Fig. 
7)[50]. TPP
+
 is a lipophilic cation that enables the molecule to enter and accumulate inside the mitochondria as a result 
of the electrochemical gradient. Coenzyme Q plays an integral role in Complex II of the mitochondrial respiratory 
chain. By positive charge, mitoQ accumulates in mitochondria and it has been used to modulate ROS in the 
mitochondrial matrix [51]. It has been reported that mitoQ also exerts protective effects on cells by reducing free 
radicals, decreasing oxidative damage and maintaining mitochondrial functions[52]. 
 
 
 
 
Figure7.Design strategy of MitoQ. 
 
4. Cholinesterase and OS 
The systematic biochemical investigation of the brain, between the late 1960s and early 1970s, established that a loss of 
cholinergic function in the CNS contributes to the cognitive decline associated with AD [53]. A support for this 
perspective came when Perry et al. reported a substantial neocortical deficits of choline acetyltransferase (ChAT), the 
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enzyme responsible for the synthesis of acetylcholine (ACh)[54].  The “cholinergic hypothesis” was postulated on this 
basis. According to this hypothesis, the  degeneration of cholinergic neurons in the basal forebrain is associated with the 
loss of cholinergic neurotransmission in the cerebral cortex as well as in other cerebral areas and these events 
significantly contributed to the deterioration in cognitive function of AD patients[55]. 
In the mammalian brain, the most prominent enzyme involved in acetylcholine hydrolysis is acetylcholinesterase 
(AChE). AChE has two binding sites: a catalytic active site (CAS), located at the bottom of a deep narrow gorge lined 
with several aromatic amino acid residues, and a peripheral anionic site (PAS) uncovered at the entrance. The PAS is 
involved in a secondary non-cholinergic function that includes the promotion of Aβ formation associated with 
deposition of senile plaques/neurofibrillary tangles in the brain of AD afflicted individuals. 
Additionally, butyrylcholinesterase (BuChE) can also hydrolyse acetylcholine in the brain and may play a critical role 
in cholinergic transmission[56], so the inhibition of this enzyme leads to an increase in the acetylcholine concentration 
of the synaptic cleft and it is thus expected to enhance cholinergic transmission and ameliorate cholinergic deficit[57]. 
Despite outstanding efforts to develop innovative therapies for Alzheimer’s disease, acetylcholinesterase inhibitors 
(AChEIs) still continue to represent the most important class of compounds for the treatment of mild and moderate 
forms of AD [58]. These drugs have proved themselves useful in maintaining cognitive and functional abilities in most 
AD patients. Therefore, many compounds endowed with both acetylcholinesterase inhibitory activity and antioxidant 
properties have been synthesized in order to produce additional benefits preventing A mediated oxidative damage in 
AD patients [59, 60]. A wide plethora of new hybrid drugs have been recently published [61-64]. 
Many examples include multi-target compounds of tacrine, the first AChEI approved for the treatment of AD. In order 
to combine its potent AChE inhibition with other pharmacological properties, such as antioxidant and metal chelating 
activities, this drug was appropriately conjugated with many other pharmacological moieties.  
Melchiorre’s research group developed Lipocrine (Fig. 8), a multitarget compound in which lipoic acid, a natural 
antioxidant, was combined with tacrine. In in vitro tests, lipocrine turned out to have better AChE and BuChE inhibitory 
activity than tacrine (IC50 = 0.253±0.016 nM and 10.8±2.5 nM, vs IC50 = 424±21nM and 45.8±3.0 nM respectively) 
[60]. 
Moreover, as highlighted from kinetic analyses, this compound resulted to be a mixed AChEI type, able to bind both 
catalytic (CAS) and peripheral (PAS) sites of AChE. Results obtained in in vitro models showed that lipocrine induced 
a significant inhibition of AChE-induced Aβ aggregation. As regard the antioxidant properties, lipocrine was able to 
counteract the ROS production (64% inhibition at 50 µM) more effectively than lipoic acid[65]. Altogether the 
pharmacological multitarget profile of lipocrine leads to consider it as an attractive multicomponent drug for the 
treatment of AD[66]. 
Another molecule, obtained through the combination of two molecules of tacrine, namely bis(7)-tacrine, exhibited a 
higher AChE inhibition potency and a better pharmacological profile than native compound; with the aim of improving 
the antioxidant profile, bis(7)-tacrine was subjected to chemical manipulations in order to improve its biological profile 
as radical scavenger[67]. In particular, the alkyl chain of bis(7)-tacrine was replaced by cystamine (Fig. 8), a well-
known molecule endowed with antioxidant and neuroprotective properties[68].  
The cystamine-tacrine dimer [69] showed a pharmacological profile comparable to bis(7)-tacrine, as regard the 
inhibition of both cholinesterases (AChE IC50= 4.4 ± 1.7M and BuChE IC50= 6.7 ± 1.6M) and the inhibition of the 
Aβ aggregation. Unlike bis(7)-tacrine, cystamine-tacrine dimer displayed antioxidant activity due to the contribute of 
disulfide bridge. Two different pathways PI3K/Akt and ERK1/2 seem to be linked to the neuroprotective effects. As 
regards the pathway PI3K/Akt, it is able to protect neurons from apoptosis, and inhibits the Aβ-induced neurotoxicity. 
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Moreover, it was demonstrated that cystamine-tacrine dimer can phosphorylate also ERK1/2, demonstrating a different 
mechanism of action in comparison with bis(7)-tacrine that does not show any effects on Akt or ERK1/2 kinases[70]. 
Recently, Pi and collaborators developed tacrine–ferulic acid hybrids (TAFA)[71], and tacrine-caffeic acid hybrids 
(TACA)[72] as potential AD therapeutics. Enzyme kinetic studies of both series of compounds showed that the new 
molecules were able to simultaneously interact with the catalytic site and the peripheral anionic site (PAS) of the AChE 
[71]. 
Among these compounds, T6FA (Fig. 8), inhibited the AChE-induced Aβ1–40 aggregation by 50.27% and 20.23% at 100 
µM and 50 µM, while the effects of native drugs alone (FA and tacrine) on Aβ aggregation were lower or not detectable 
at such concentrations. This multifunctional dimer protects HT22 cells from glutamate-induced cytotoxicity and 
decreases the level of ROS induced by glutamate. Besides, T6FA dramatically provokes the Nrf2 nuclear translocation, 
and the activation of the ARE-dependent transcription. All results suggest that T6FA can be an useful tool for cognitive 
impairment and may be considered as a promising multifunctional drug candidate for neurodegenerative diseases[71].  
Subsequently, in order to widen the pharmacological profile of the compounds TAFA and TACA, a series of TAFA and 
TACA was synthesized [72, 73], in which the linker was replaced by the 1,3-diamino-2-propanol chain. 
Within this series, compound 3 (Fig. 8) displayed a good ability to inhibit the A1–42 self-aggregation, with percentage 
value of 53%, even if it exhibited modest BACE1 and AChE inhibitor activities. Moreover, tacrine–caffeic acid hybrid, 
showed antioxidant properties with scavenging percentage values ranging from 60.87% to 90.36% and comparable to 
caffeic acid (44.10% and 90.27% respectively). Compound 3 also proved to chelate copper ions in UV–vis spectrometry 
thus delineating a multi-functional AChEI-antioxidant-chelating profile [73]. 
Given the growing interest on natural-based drugs, recently, Santos [74]explored a set of hybrid compounds obtained by 
the conjunction of the tacrine moiety with S-propargylcysteine. This combination was aimed at improving both the 
cholinergic system and neuroprotective capacity. The two main molecular moieties have been combined through linkers 
that were able to ensure a dual binding interaction with CAS and PAS of AChE. 
An analysis of the results reveals that Tacrine–SPRC(Fig. 8) showed an AChE inhibitory activity with IC50 values of 
1.21 M. Moreover this molecule displayed a combined role in both preventing A-induced toxicity and reducing 
H2O2-induced oxidative stress in a cellular context. Even if the scavenger activity assessed by the DPPH method 
resulted to be quite low, a significant neuroprotective activity was observed in in vitro assays. This apparent mismatch 
could be explained, at least in part, by the capability of this compound to react with sulphydryl groups of antioxidant 
enzymes such as the intracellular glutathione (GSH). Finally, this multitarget compound showed to be able to chelate 
Cu(II) (pCu = 7.14–7.5) throughout the diamine-linker within the two main molecular units [75]. The most promising 
results were achieved by Tacrine–SPRC that could be suggested as potential lead compound toward AD therapy[74]. 
12 
 
 
Figure8.Design strategy of multitarget tacrine derivatives. 
Evidence indicates that BuChE might be a co-regulator of the activity of the neurotransmitter Ach [76].  In a more 
recent study, structural scaffold of donepezil has been used as a lead-structure to design multitarget-directed ligands. 
Donepezil is the second drug approved by the U.S. Food and Drug Administration for the treatment of mild to moderate 
AD and shows a greater affinity for AChE than for BuChE. In particular, this observation prompted Benchekroun [77] 
to develop multifunctional molecules able to restore acetylcholine levels and reduce oxidative stress. These compounds 
were designed starting from benzylpiperidine-scaffold of donepezil and ferulic acid (Fig. 9). Among the synthesized 
hybrids, DFAH showed a strong antioxidant potency (8.71) which resulted to be higher than that of ferulic acid (3.74). 
DFAH displayed also a good BuChE inhibitory activity displaying to be 198-fold more potent than donepezil (IC50 = 
10.39 ± 0.48 nM vs 2057 ± 290 nM). In addition, the new compound revealed to be able to trap toxic radical species, 
preventing the neuronal damages strictly related to the oxidative stress [77]. On the whole, the multitarget profile of 
DFAH points out that also this compound could be further investigated as a potential multifunctional neuroprotective 
agent for the treatment of AD. 
Similarly, a novel series of molecules, obtained by fusing the cholinesterase inhibitor donepezil and the antioxidant 
ebselen, were described as potential multi-modal agents to manage the AD [78]. Ebselen (2-phenyl-1,2-
benzisoselenazol-3(2H)-one) is a lipid-soluble cyclic selenenamide that has been extensively studied as the GPx mimic 
(Fig. 9). It protects cells by catalyzing the reduction of peroxides with glutathione. Besides, a recent study, indicates that 
this molecule is able to inhibit iron-induced tau phosphorylation[79]. Within the new series of derivatives, SE-518 
turned out to be the most potent AChE inhibitor (IC50=0.097M  for AChE) with a moderate BuChE inhibitory activity 
(IC50=1.586 M ). Moreover, it also proved to scavenge H2O2 and peroxynitrite and to have additional glutathione 
peroxidase-like activity, without any toxicity in mice at a dose of 2000 mg/kg. Further permeability studies performed 
in in vitro models indicated that SE-518 is able to penetrate the central nervous system thus highlighting that also this 
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kind of conjunction could be successfully accomplished for the discovery of new lead compounds for the treatment of 
AD. 
 
 
Figure9.MTDL strategy of Donepezil derivatives. 
 
5. NrF2/ARE and OS 
As a part of a delicate equilibrium, since ROS induces to oxidative damage, also the decrease in antioxidant defenses 
contributes to worsen the neurodegeneration. Several lines of evidence suggest that a transcriptional increase of the 
activity of the Nrf2/ARE pathway leads to an increase of antioxidant defenses throughout the transcription of anti-
inflammatory and antioxidant genes. Consistently, this pathway may represent a compelling target to halt or prevent the 
onset of neurodegenerative diseases such as AD and Parkinson’s diseases [80, 81]. 
Nuclear factor E2-related factor 2 (Nrf2) is a master regulator that induces the expression of a variety of cytoprotective 
and detoxificant genes including antioxidant enzymes, anti-inflammatory mediators and several transcription factors 
involved in mitochondrial biogenesis. Nrf2 bound to its inhibitor kelch-like ECH-associated protein (Keap1) in the 
cytosol thus preventing the Nrf2 translocation into the nucleus.  
OS is able to disrupt the complex Nrf2-Keap1 thus inducing the translocation of Nrf2 into the nucleus and then 
promoting the activation of the Antioxidant Response Element (ARE), a promoter region of genes encoding various 
antioxidants and detoxifying enzymes. Nrf2 also antagonizes the transcription factor Nuclear Factor-κB (NF-κB), which 
regulates the expression of inflammatory genes, assuming also a key role against neuroinflammation [82]. Moreover, 
Nrf2 is considered a stress-sensing genetic transcription factor since its expression generally declines with age. Suh et al 
showed a marked age –related loss both in total and nuclear Nrf2 levels, suggesting therefore an attenuation in Nrf2-
dependent gene transcription [83]. In addition to that, the release of Nrf2 from keap1 is significantly impaired in AD. 
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This effect could be related to the reduction observed in the frontal cortex of AD patients of both p62 gene expression 
and cytoplasmic p62 protein levels [84]. P62 could bind to the Keap1 thus hindering the interaction of Keap1 with Nrf2 
transcription factor, which, in turn, induces the stress responsive cellular defence genes. Nrf2 also stimulates the 
expression of p62 protein with a positive feedback loop, between the expression of p62 protein and Nrf2-mediated 
stress responses. Therefore, a decrease in the level of p62 protein can perturb the signalling pathways of Nrf2, thus 
increasing OS [85]. Moreover, the lack of p62 expression induces an aggravation of tau pathology in neurons by 
increasing GSK3β activity as well as by decreasing the synaptic function with loss of working memory and neuronal 
apoptosis [86].  
Besides its role in regulating cellular anti-oxidative response, Nrf2 pathway shows also anti-inflammatory activity [87] 
thus representing a new therapeutic approach for suppressing or reducing the inflammatory stress. Therefore, disruption 
of Nrf2/ARE pathway may contribute to induce or worsen the main hallmarks of neurodegeneration such as oxidative 
stress, misfolded proteins aggregation, excitotoxicity and inflammation. 
A wide range of dietary phytochemicals showed to induce the expression of enzymes involved in cellular antioxidant 
defence. In particular natural compounds such as sulphorafane, resveratrol, allyl sulfides, epigallocatechin gallate and 
curcumin, proved to activate the Nrf2 pathway and to produce neuroprotective effects [88]. It has to be underlined that 
these molecules possessed an intricate polypharmacology, including anti-amyloidogenic, anti-oxidative, and anti-
inflammatory properties [23]. Unfortunately, phytochemicals display a poor bioavailability, thus hindering their 
application in therapy. Several ongoing studies aim at looking for new strategies to improve the ADME profile of these 
molecular entities[89-91], in order to use them as multitarget therapeutics for the treatment of neurodegenerative 
diseases. 
Sulforaphane [1-isothiocyanato-(4R,S)-(methylsulfinyl)butane] (SFN) (Fig. 10) is an isothiocyanate derivative found in 
broccoli and other cruciferous vegetables. SFN directly interacts with Keap1 by covalent binding to the thiol groups of 
the reactive cysteine residues, used by the protein as sensors of the intracellular redox state. SFN showed to increase 
Nrf2 and several ARE-dependent antioxidant enzymes, such as Glutathione Reductase (GR), GPX, glutaredoxin 
(GLRX), thioredoxin (TX), thioredoxin reductase (TR), Heme oxygenase 1 (HO1), and NQO1, in different cell systems 
[92]. In 2013 Kim et al demonstrated that administration of SFN ameliorated cognitive function of Aβ-induced AD 
acute mouse models[93]. Although the exact mechanism of action of SFN in AD has not been established yet, the 
authors suggest that SFN can be of help in cognitive impairment and may defend the brain from amyloidogenic 
damages, indicating that antioxidants, such as SFN, can be a complementary yet promising strategy to approach AD 
treatment.  
Following those premises, in 2015 Egea et al. synthetized compound ITH12674, a hybrid molecule designed to exert a 
dual drug-prodrug mechanism of action, which combine SFN and melatonin structures[94] (Fig. 10). Melatonin is a 
neuro-hormone synthesized in the pineal gland. Its expression decreases with aging. Melatonin is already in use in AD 
therapy for its chrono-biological properties that make it capable of correcting the circadian rhythm disorders observed 
in AD patients. Moreover, it has been widely reported as a potent antioxidant and scavenger compound, also able to 
induce antifibrillogenic effects in both in vitro and in vivo models[95]. ITH12674 collects the melatonin and SFN 
features in one molecule with an improved neuroprotective profile compared with that of the parent compounds. 
ITH12674 exerted a concentration-dependent protective effect in cortical neurons subjected to OS, also decreasing 
mitochondrial ROS production and increasing GSH levels in cortical neurons. In addition to that, this molecule was able 
to enhance the Nrf2–ARE response in transfected HEK293T cells and to protect organotypic cultures of hippocampal 
slices from stress by increasing the expression of HO-1 and reducing free radical production [94].  
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Likewise, the same group synthetized compound 4 [96], a multi-target hybrid structure derived from the conjunction of 
melatonin and ethyl cinnamate (Fig. 10). Cinnamate esters are moderate Nrf2 inducers, while the corresponding free 
cinnamic acids proved to be inactive. Interestingly, the Nrf2-induction potency of cinnamate esters is influenced by the 
position of the substituents on the aromatic ring. Among the series of new synthesized hybrid-molecules, compound 4 
showed a free radicals scavenger activity four-fold more potent than melatonin and a significant Nrf2 induction effect 
with the best antioxidant activity, maybe related to its electrophilic character. Compound 4 displayed high 
neuroprotective potency in an OS model too. Also this effect resulted higher than the parent compound melatonin in 
two different models of neurodegeneration associated with AD and brain ischemia [96]. 
 
 
Figure10. Structures of hybrids obtained by the conjunction between Ethyl cinnamate and Melatonin (Compound 4) 
and Melatonin and SFN (ITH2674). 
6. Metal chelating and OS 
Disruption of metal homeostasis is included among the major pathological features playing important roles in the 
progress of AD. Iron (Fe), copper (Cu), and zinc (Zn) are the triad of transition elements involved in the metal 
hypothesis. Brains affected by AD suffer from metallostasis, or fatigue of metal trafficking, which leads to 
redistribution of metals into inappropriate compartments [97].  
Levels of Fe, Cu, and Zn were found enriched in AD due to a dysfunction of the corresponding regulatory system.While 
reporting of zinc and copper levels in AD-affected brains has been inconsistent until now, iron accumulation occurs in 
AD patient’s cortex and not in cerebellum [98, 99], consistently with the anatomical profile of such neurodegeneration. 
All three metals bind Aβ and accelerate its aggregation into insoluble precipitates thus increasing metal sequestration 
into amyloid deposits. Additionally, Zn bound to A may hinder the proteolytic cleavage site preventing its degradation 
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by matrix metalloproteases. Moreover, these metals are also involved in tau pathology: indeed, both Cu and Fe(II) 
metals induce tau hyperphosphorylation [100], while Zn modifies tau conformation and induces both  fibrils formation 
and aggregation of tau-protein[101]. Interferences of metals with APP processing and function were also found. 
Furthermore, investigations on the Cu–Aβ complex lead to speculate that the complex-induced toxicity may involve the 
inhibition on human cytochrome c oxidase and the production of H2O2 via a catalytic cycle [97]. 
All these processes contribute to generate OS damage, making the design of specific multitarget-compounds endowed 
of metal chelating properties and anti-OS activity a challenging issue to restore metal homeostasis and reduce OS in AD 
brains. Since Cu exhibits the greatest implication with dyshomeostasis in amyloid plaques and increasing of Aβ 
deposition, Cu is the main metal studied for this purpose. On the contrary, despite the confirmed role of Fe in AD 
pathogenesis, the number of iron chelator-based drugs, is limited[97].  
Clearly, being AD a multifactorial disease, the design of new molecular entities, which combine chelating scaffolds 
with functional moieties able to hit other important disease targets, is a synthetic strategy widely applied in the design 
of novel combined metal chelating-antioxidant compounds. For instance GS(HQ)H is a hybrid molecule linking the 
scaffolds of 8-hydroxyquinoline (8HQ) and GSH [102] (Fig. 11). The molecule joins the metal chelating function of 
8HQ, which is the most common nucleus used for the development of metal chelating multi-target anti-AD drugs, and 
the antioxidant effect of GSH. GS(HQ)H displays a good cellular neuroprotective effect and antioxidant properties 
against H2O2 insult and against 8HQ-induced OS. The new molecule exhibits affinity for Cu(II) and Zn(II) comparable 
to that of 8HQ. Moreover, GS(HQ)H seems to be able to reach the BBB, where it displays a good capability in 
removing Cu(II) and Zn(II) from the Aβ-peptide in vivo, without causing any depletion of these metal ions [102].  
Besides, 8HQ scaffold was also fused with resveratrol molecular scaffold to obtain hybrids endowed with Aβ 
interacting, anti-OS and chelating activities [103]. The resulting set of 8HQ-resveratrol hybrid molecules exhibited 
excellent MTDL properties such as the inhibition of self-induced and copper(II)-induced Aβ aggregation, as well as 
potential antioxidant and biometals chelation properties. Within the series, derivative (E)-5-(4-hydroxystyryl)quinoline-
8-ol 5 (Fig. 11) possessed the best profile: 5 was able to disassemble the well-structured Aβ fibrils generated by self- 
and Cu(II)-induced Aβ aggregation. Compound 5 revealed also to exert a control on Cu(I/II)-triggered hydroxyl radical 
production by halting Cu redox cycling via metal complexation. Furthermore, 5 also demonstrated a potent oxygen 
radical absorbance capacity. Notably, 5 showed to pass the BBB and did not show acute toxicity in vivo at doses of up 
to 2000 mg kg
−1
[103]. 
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Figure11. Structures of hybrids obtained by the conjunction between GSH and 8-HQ (GS(HQ)H) and 8-HQ and 
Resveratrol (Compound 5). 
7. Inflammation and OS  
Considerable evidence gained over the past decade has supported the conclusion that both a prominent activation of 
inflammatory processes and the innate immune response are associated with AD pathology [104, 105]. The major 
players involved in the inflammatory process are microglia, astrocytes, macrophages and lymphocytes; all of them have 
many critical roles in the release of inflammatory mediators such as cytokines, chemokines, neurotransmitters and ROS. 
The release of mediators leads to recruitment of monocytes and lymphocytes through the BBB as well as activation of 
additional microglia, inducing further release of other inflammatory factors. In addition, both the microglia and 
astrocytes have been shown to generate A that seems to play a key role in driving microglia activation and the 
neuroinflammatory response[106].  
Glial cells, which constitute a source and a target for free radical species, as well as contribute to neuroinflammatory 
processes, promote and aggravate the oxidative damage and hamper neuronal viability[107].  Since oxidative stress and 
neuroinflammation are strongly correlated, it is not surprising to know that, among the strategies being followed to 
design new potential anti-AD drugs, the combination of traditional anti-inflammatory and antioxidant molecules is also 
pursued.  
Non-steroidal anti-inflammatory drugs (NSAIDs) including the over-the-counter (OTC) drugs ibuprofen and naproxen, 
shown to reduce Alzheimer’s disease risk [108]. Moreover, NSAIDs proved (i) to alter the conformation of A 
peptides, thus exerting an anti-aggregating activity, and (ii) to induce the expression of amyloid-binding proteins[109]; 
despite countless benefits, chronic use of NSAIDs is limited by their gastric toxicity.  
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On this basis, more recently, Cacciatore et al.[110]explored a series of novel multitarget-NSAIDs derivatives obtained 
by the conjunction of (S)-naproxen or (R)-flurbiprofen with (R)-lipoic acid (LA), through alkylene diamine linkers. 
This combination was designed to increase the brain permeability and to reduce the gastric toxicity commonly 
associated to the use of traditional anti-inflammatory drugs. Among the new synthesized compounds, containing the 
linker between amino ethylene (R)-flurbiprofen and LA, AL7 (Fig. 12), demonstrated to possess the most favorable 
chemical stability and thus it was selected for further investigations on two different cell lines, THP-1 (leukemic 
monocytes) and U937 (lymphoblast lung from human), to evaluate the induced attenuation of the damage; results 
showed a marked increase of cellular vitality after 48h in U937 cells at the concentrations of 0.1 and 1M. ROS 
production was measured using 2`,7`-dichlorofluorescein (DCF), as a fluorescent probe. After pretreatment with the 
new compound, the ROS production induced by phorbol 12-miristate 13-acetate (PMA), in THP-1 cells (leukemic 
monocytes), was significantly reduced after 24h (0.1 M) and after 48h (1 M) (44.82% and 35.50%, respectively). 
Moreover, the new molecule also reduced the A -induced ROS production at a dose of 1M in both cell lines. Finally, 
the modulation of the expression of COX-2, IL-1 and TNF- were observed, thus indicating that AL7 is also endowed 
of anti-inflammatory properties. These results reveal that AL7 could represent a potential lead-multifunctional-NSAID 
worthy of further evaluation in suitable models of AD. 
 
Figure 12.Design strategy of AL7. 
 
It is widely recognized that NSAIDs can regulate gene expression via the interaction with a class of nuclear receptor 
superfamily members, namely Peroxisome Proliferator-Activated Receptors (PPARs) [111]. Three different PPAR 
genes (PPARα, PPARβ also called δ, and PPARγ) have been identified, each one with splicing variants. PPARγ, mainly 
expressed in microglia and astrocytes, has been shown to play essential roles in energetic metabolism, adipocyte 
differentiation, insulin sensitization and tumor suppression. The PPAR-γ activation induces a decrease in neuronal death 
preventing both oxidative and inflammatory processes implicated in cerebral injury. To date, extensive  and  compelling  
studies indicate that PPAR-γ  ligands inhibit  the  production  of  proinflammatory  cytokines, including IL-1β, TNF-α 
and IL-6, in human monocytes  and  arrest  the  differentiation  of monocytes  into  activated  macrophages[112-114]. 
A collected body of evidence shows that  PPARγ activation can lead to suppression of cellular APP levels. Recently, 
Wang et al identified astragaloside IV (AS-IV) as a natural PPARγ agonist. The authors proved that the treatment of  
cultured SH-SY5Y cells with this selective PPARγ ligand increases the activity of PPARγ and inhibits BACE1 resulting 
in a significant decrease of Aβ level [115]. Globally, the multi-functional effects induced by PPAR activation prove to 
positively influence the pathology of Alzheimer’s disease [116]. Their ability to ameliorate the inflammatory status of 
the AD brain (by decreasing the production of proinflammatory molecules), and to reduce the amyloidogenic Aβ-
production, underlines the beneficial effects of PPARγ agonists for future AD therapy.  
Nowadays, PPARγ agonists are extensively investigated as therapeutic agents. The benefits in AD are addressed to their 
ability to regulate the transcription of a wide variety of oxidative, inflammatory, fibrotic, and neuronal survival genes, 
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although also transcription-independent effects may be involved [117]. Indeed, it has been reported that PPARγ agonists 
promote the amyloid clearance by affecting the overexpression of Apolipoprotein E (ApoE), a lipoprotein, mainly found 
in liver and brain and able to enhance both the degradation and phagocytosis of A𝛽 in the microglia and astrocytes 
[118]. 
Thiazolidinediones (TZDs) (Fig. 13) belong to the class of PPARγ agonists exhibit several pharmacological activities 
that prove to be beneficial for the treatment of neurodegenerative diseases. Besides the inhibition of neuroinflammation, 
TZDs demonstrate to enhance synaptic plasticity, ameliorate mitochondrial function and reduce tau 
hyperphosphorylation [119]. TZDs were introduced in the late 1990s as a class of oral antidiabetic drugs for the 
treatment of type 2 diabetes. Within this class, pioglitazone (Actos, Takeda Pharmaceuticals North America, Inc.) and 
rosiglitazone (Avandia, GlaxoSmithKline), are now in clinical trials for the treatment of AD. Rosiglitazone and 
pioglitazone, proved to relieve neurodegeneration and reduce cognitive decline associated with AD [120, 121]. In 
particular pioglitazone is undergoing Phase III of clinical trials (ClinicalTrials.gov Identifier:NCT02284906) for the 
treatment of mild cognitive impairment due to Alzheimer's Disease [122] whereas a phase III study for rosiglitazone has 
been completed in 2009, but the results haven’t been published yet (ClinicalTrials.gov Identifier:NCT00348140)[123]. 
 
 
 
Figure 13. Structure of thiazolidinediones:Rosiglitazone (a) and Pioglitazone (b). 
 
8. Nature-based ligands as a source to design multitarget drugs 
Nature has been always considered an inexhaustible source of bioactive substances with beneficial and/or healing 
properties. Several important drugs that have revolutionized treatment of serious diseases were born from natural 
products and/or from their pharmacophores. Many recent reviews have provided important insights on this current issue 
[124-126]. In particular, Newman and Cragg have recently published an interesting review in which a detailed analysis 
of the key role played by natural products in the drug discovery process  has been highlighted [127].   
Since natural products often already possess established pharmacological activities, including off-targets effects, the 
concept to use Nature as primary resource to find “lead-scaffolds” for the synthesis of new drugs is strongly pursued. 
Therefore, the identification of “nature-based scaffolds” suitable for the development of new multitarget drugs, is 
widely investigated as a possible starting point to design new treatments for several diseases, including AD. Herein, we 
briefly discuss the main phytochemicals and the corresponding pharmacological effects assessed in in vitro or in vivo 
AD-models. (Table 1)  
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Table 1. Effects of natural products on AD. 
 
Among the well-known natural compounds widely studied in several diseases, the flavones are largely known to bind to 
the benzodiazepine site on the GABA-A receptor resulting in sedation, anxiolytic or anti-convulsive effects[128]. 
Among them, Apigenin (4',5,7-trihydroxyflavone) is emerging as a potential lead scaffold for the development of anti -
AD drugs. This polyphenol has been found in high amounts in the ligulate flowers of the chamomile plant and it 
resulted to be scarcely toxic and non-mutagenic and exhibited well-established anti-inflammatory, antioxidant, and 
Structure Phytochemicals Effects 
 
Apigenin Block of Aaggregation 
 
Rosmarinic acid 
Protection of PC12 cells from  
A-induced neurotoxicity 
 
(−)-Epigallocatechin-3-
gallate 
Metal chelator 
Anti-inflammatory 
 
Curcumin Inhibition of A insult 
 
Huperzine A 
NMDA receptor modulator 
Neuroprotective 
 
Linalool 
Inhibition of acetylcholinesterase 
in vitro 
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anticarcinogenic activities. A great body of evidence shows that it strongly decreases the levels of IL-6 and TNF- in 
activated in murine microglia Interferon gamma (IFN-) through its effect on phosphorylation of STAT1[129]. Anti-
inflammatory effect of Apigenin seems to occur via the reduction of the expression of iNOS and COX-2 in both 
microglial and macrophage mouse cells[130]. Besides the protection against neuroinflammation, Apigenin promotes an 
increase of GSH levels and reveals to be a good free radical scavenger. Both properties cooperate to the significant 
neuroprotective effect of this molecule, against the oxidative stress. Moreover, another study performed by Zhao et al. 
proved that the neuroprotective effect of Apigenin could be also explained by the significant decreasing of amyloid 
deposition via a down-regulation of BACE1[131]. Latterly, Hang et al. have shown that the antioxidant properties of 
Apigenin were dependent on activation of Nrf2 signaling [132]. The intrinsic pharmacological properties of Apigenin 
allow us to consider this molecule a suitable and promising natural scaffold for the development of new MTDL for AD 
therapy. 
Another important phytochemical which proved to protect neuronal cells from A-induced neurotoxicity is the 
Rosmarinic acid (RA)[133]. RA, the major constituent of sage, is an ester of caffeic acid (CA) and 3,4-
dihydroxyphenyllactic acid and it is one of the most important and well known natural antioxidant compounds, which 
exhibits neuroprotective effects in different models of neuroinflammation and neurodegeneration[134, 135]. The 
compelling results obtained by several studies performed in in vitro models of AD for both sage and RA, prompt 
researchers to further investigate this spice for the treatment of AD and eventually to explore the possible use of RA as 
a therapeutic approach in AD. 
 
The polyphenolic compound (−)-epigallocatechin-3-gallate (EGCG) is the major catechin found in green tea; the 
pharmacological effects induced by this phytochemical have the potential to modify several human pathologies, 
including neurodegenerative ones. EGCG was demonstrated to be a powerful hydrogen-donating antioxidant, but also a 
free radical scavenger of ROS and RNS in vitro. The antioxidant effects of EGCG are addressed to the presence of 
phenolic moieties that are sensitive to oxidation, generating quinone species [136]. It has also been demonstrated that 
EGCG exerts an antioxidant effect by activating the Nrf2 signaling pathway, which initiates the transcription of a series 
of cytoprotective genes [137]. EGCG demonstrated also a significant efficacy in restoring β-amyloid-induced 
behavioral imbalance in rats, as well as the memory and coordination abilities. Treatments with the polyphenol are able 
to restore altered mitochondrial membrane potential, mitochondrial respiratory rates and ROS production or ATP levels 
[138]. Moreover, it should be noticed that also the decline induced by EGCG in MAO activity could provide protection 
against oxidative neurodegeneration. 
As previously discussed, the pivotal role of iron in neurodegeneration was already established and recent studies 
explored the EGCG activity in chelating the Fe
2+
ion, demonstrating the neuro-restorative activity and Fe
2+
-chelating 
properties[139] of the tea polyphenol. In hippocampal neurons, the examined natural compound exerted a protective 
effect against ischemic insult, but it also decreased the A1–42-induced neurotoxicity of EGCG [140]. Then, EGCG has 
proved to possess such a wide range of biological effects (neuropathological, neurochemical, and cognitive benefits) to 
be considered a promising compound as well as a safe and effective therapeutic agent against AD. Nowadays, EGCG 
has completed a phase II/III clinical trial aimed at evaluating the efficacy and safety in the Early Stage of Alzheimer´s 
Disease (ClinicalTrials.gov Identifier: NCT00951834)[141]. 
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Curcumin (1,7-bis [4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-dione) or diarylheptanoid is a bioactive 
polyphenol found in the rhizomes of Curcuma longa L. Curcumin like other antioxidants, it protects brain cells and 
their mitochondria against amyloid beta-induced toxicity and also inhibiting the formation of abnormal proteins [142]. 
This natural compound also possesses an inhibitory effect against the expression of enzymes such as COX-2 and 
inducible nitric oxide synthase (iNOS), thus causing a marked reduction in the levels of prostaglandin E2 (PGE2) and 
NO. A very recent experimental study showed that the curcumin attenuates oxidative stress by modulating Nrf2-Keap1 
pathway and then leading to increases in the expression and activity of HO-1[143]. In addition to that, curcumin is a 
potent inducer of HO-1 in vascular endothelial cells. The pre-treatment with tin protophorphyrin IX, an inhibitor of HO-
1 activity, proved to completely abolish the curcumin-mediated cytoprotection against oxidative stress [144]. Moreover, 
it reduces levels of the astrocyte marker glial fibrillary acidic protein (GFAP) and prevents A42 oligomers formation 
and toxicity.  
Several studies in AD animal models have evaluated the effects of these multiple mechanisms on learning and memory. 
Curcumin supplements administration, even after the occurrence of Alzheimer’s-like symptoms, results in less mistakes 
on memory-dependent tasks, and improved performance on mazes. Both results show positive effects on functions of 
both reasoning and memory [145]. Today, Phase II clinical trials studies are ongoing in order to define the efficacy and 
the safety of high-bioavailability curcumin formulation (Longvida) in AD patients.(ClinicalTrials.gov Identifier: 
NCT01001637)[146]. 
 
Huperzine A (HupA) is a sesquiterpene alkaloid found in the Huperzia Serrata, a plant widely used  in the traditional 
Chinese medicine for centuries [147]. HupA acts as a potent, highly specific and reversible inhibitor of 
acetylcholinesterase (AChEI). It crosses the blood–brain barrier easily. Ever since its isolation in 1986, Huperzine A, 
progressed as the most-promising and widely-studied reversible AChE inhibitor and it showed to be efficient drug 
candidate with potential anticholinesterase effects. Indeed, it has been licensed as anti-AD drug in China. The AChE 
inhibitory activity, pharmacology and the detailed properties of Huperzine A let to consider such a molecule as a 
promising agent for treating dementia (including AD)[148, 149]. Several clinical trials suggested that HupA exerts 
positive beneficial effects in AD patients without any severe adverse effects [150, 151]. Good pharmacokinetic profile 
with rapid absorption, wide distribution in body, good BBB value and low to moderate rate of elimination make the 
Huperzine A  more attractive than other drugs [151]. HupA also shows a high bioavailability after oral administration, 
ability to penetrate into the CNS, long duration of action and minimal side effects. Administration of HupA 
significantly prevents the decrease caused by Aβ in mitochondrial active respiration and ATP synthesis. Moreover, 
evidence highlight that huperzine is capable to reverse or attenuate cognitive deficits in several animal models. In order 
to assess the safety and efficacy of the HupA in the treatment of AD, a phase II clinical trial has been performed and 
completed in 2008. No results have been published yet (ClinicalTrials.gov Identifier: NCT00083590)[152]. 
 
Linalool, a natural compound of coriander, has been reported to have anti-inflammatory effects mediated by TNF-, IL-
1, NO and PGE2. The coriander possesses strong antioxidant properties related to its ability to decrease the stimulation 
of lipid peroxidation and protein oxidation. In in vitro tests, Linalool showed to inhibit with a good efficacy 
AChE[153]. Moreover, Zheng et al. reported that linalool exerts anti-inflammatory effects through the induction of Nrf2 
nuclear translocation and the expression of HO-1.[154] An in vivo study performed on aged mice and transgenic model 
of AD (3xTg-AD) showed that a chronic treatment with linalool induced a significant reduction of A-deposition, and 
in the levels of the pro-inflammatory markers p38 MAPK, NOS2, COX2 and IL-1β [155, 156]. All these data suggest 
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that linalool is able to reverse the histopathological hallmarks of AD and to restore cognitive functions via an anti-
inflammatory effect.  
 
9. Conclusion 
In the last years, the development of ligands endowed of a polypharmacological profile is a strategy highly pursued in 
medicinal chemistry field. Several pathologies characterized by an intricate etiology such as cancer, cardiovascular and 
neurodegenerative diseases have witnessed the failure of numerous clinical trials. These failures are probably due to the 
lack of efficacy of mono-targeted therapy and this is the first reason why the attention of medicinal chemists has been 
directed toward the multitarget strategy. As concerns neurodegenerative diseases, and in particular AD, several phase 
III trials failed to reach the clinical endpoints probably because of the complexity, not yet completely clarified, of the 
pathology itself. Therefore, the design of innovative therapies is going rapidly toward the searching for new molecules 
able to regulate the equilibrium between oxidative stress, and the hallmarks of AD such as A-aggregation, NFT-
tangles, metal disomeostasis and neuroinflammation. To date, significant progresses in this field have been done, even 
if the complexity of this pathology still represents the main drawback to find successful multitarget therapies to be 
further investigated in clinical trials. Nutraceuticals play an increasingly important role in the treatment of various 
pathological states and consequently recent trends highlight that bioactive molecules found in functional foods and 
supplements play a key therapeutic role in several diseases. Since Nature is an almost endless source of bioactive 
compounds, it could be interesting to use it also as primary resource of bioactive moieties or “Lead-Nature-based-
Scaffolds” (LNSs) for the synthesis of new multitarget neuroprotective drugs. Future directions in the comprehension of 
the existing links between OS and the hallmarks of AD as well as their correlation with neurodegenerative events, will 
be a smart challenge to fine-tune the multitarget strategy for the development of new effective therapeutics for AD.  
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